227 related articles for article (PubMed ID: 9617594)
1. Current treatment options for malignant melanoma.
Cohen GL; Falkson CI
Drugs; 1998 Jun; 55(6):791-9. PubMed ID: 9617594
[TBL] [Abstract][Full Text] [Related]
2. Chemotherapy and chemoimmunotherapy in disseminated malignant melanoma.
Garbe C
Melanoma Res; 1993 Aug; 3(4):291-9. PubMed ID: 7693093
[TBL] [Abstract][Full Text] [Related]
3. Treatment of metastatic malignant melanoma.
Atallah E; Flaherty L
Curr Treat Options Oncol; 2005 May; 6(3):185-93. PubMed ID: 15869730
[TBL] [Abstract][Full Text] [Related]
4. [Chemo-/immunotherapy in advanced malignant melanoma: carboplatin and DTIC or cisplatin, dtic, bcnu and tamoxifen followed by immunotherapy with interleukin 2 and interferon alpha-2a].
Kirchner HH; Atzpodien J; Poliwoda H
Med Klin (Munich); 1996 Apr; 91 Suppl 3():44-9. PubMed ID: 8692119
[TBL] [Abstract][Full Text] [Related]
5. Current therapy for malignant melanoma.
Legha SS
Semin Oncol; 1989 Feb; 16(1 Suppl 1):34-44. PubMed ID: 2465575
[TBL] [Abstract][Full Text] [Related]
6. Systemic therapy of disseminated malignant melanoma: an evidence-based overview of the state-of-the-art in daily routine.
Nashan D; Müller ML; Grabbe S; Wustlich S; Enk A
J Eur Acad Dermatol Venereol; 2007 Nov; 21(10):1305-18. PubMed ID: 17958834
[TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 for the treatment of melanoma.
Tarhini AA; Agarwala SS
Curr Opin Investig Drugs; 2005 Dec; 6(12):1234-9. PubMed ID: 16370388
[TBL] [Abstract][Full Text] [Related]
8. Rationale for intergroup trial E-3695 comparing concurrent biochemotherapy with cisplatin, vinblastine, and DTIC alone in patients with metastatic melanoma.
Flaherty LE
Cancer J Sci Am; 2000 Feb; 6 Suppl 1():S15-20. PubMed ID: 10685653
[TBL] [Abstract][Full Text] [Related]
9. Ineffectiveness of adjuvant chemotherapy using DTIC and cyclophosphamide in patients with resectable metastatic melanoma.
Balch CM; Murray D; Presant C; Bartolucci AA
Surgery; 1984 Apr; 95(4):454-9. PubMed ID: 6369594
[TBL] [Abstract][Full Text] [Related]
10. Systemic treatments for advanced cutaneous melanoma.
Anderson CM; Buzaid AC; Legha SS
Oncology (Williston Park); 1995 Nov; 9(11):1149-58; discussion 1163-4, 1167-8. PubMed ID: 8703684
[TBL] [Abstract][Full Text] [Related]
11. A phase II study of chemoneuroimmunotherapy with platinum, subcutaneous low-dose interleukin-2 and the pineal neurohormone melatonin (P.I.M.) as a second-line therapy in metastatic melanoma patients progressing on dacarbazine plus interferon-alpha.
Lissoni P; Vaghi M; Ardizzoia A; Malugani F; Fumagalli E; Bordin V; Fumagalli L; Bordoni A; Mengo S; Gardani GS; Tancini G
In Vivo; 2002; 16(2):93-6. PubMed ID: 12073777
[TBL] [Abstract][Full Text] [Related]
12. Medical management of melanoma.
Brown CK; Kirkwood JM
Surg Clin North Am; 2003 Apr; 83(2):283-322, viii. PubMed ID: 12744611
[TBL] [Abstract][Full Text] [Related]
13. Improving survival in patients with high-risk and metastatic melanoma: immunotherapy leads the way.
Agarwala S
Am J Clin Dermatol; 2003; 4(5):333-46. PubMed ID: 12688838
[TBL] [Abstract][Full Text] [Related]
14. Dacarbazine and interferon alpha with or without interleukin 2 in metastatic melanoma: a randomized phase III multicentre trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Hauschild A; Garbe C; Stolz W; Ellwanger U; Seiter S; Dummer R; Ugurel S; Sebastian G; Nashan D; Linse R; Achtelik W; Mohr P; Kaufmann R; Fey M; Ulrich J; Tilgen W
Br J Cancer; 2001 Apr; 84(8):1036-42. PubMed ID: 11308250
[TBL] [Abstract][Full Text] [Related]
15. Novel therapeutic agents under investigation for malignant melanoma.
Pavlick AC; Adams S; Fink MA; Bailes A
Expert Opin Investig Drugs; 2003 Sep; 12(9):1545-58. PubMed ID: 12943498
[TBL] [Abstract][Full Text] [Related]
16. Prognostic factors in metastatic melanoma patients treated with biochemotherapy and maintenance immunotherapy.
Minor DR; Moore D; Kim C; Kashani-Sabet M; Venna SS; Wang W; Boasberg P; O'Day S
Oncologist; 2009 Oct; 14(10):995-1002. PubMed ID: 19776094
[TBL] [Abstract][Full Text] [Related]
17. Chemoimmunotherapy with dacarbazine, cisplatin, interferon-alpha2b and interleukin-2 versus two cycles of dacarbazine followed by chemoimmunotherapy in patients with metastatic melanoma: a randomised phase II study of the European Organization for Research and Treatment of Cancer Melanoma Group.
Punt CJ; Suciu S; Gore MA; Koller J; Kruit WH; Thomas J; Patel P; Lienard D; Eggermont AM; Keilholz U
Eur J Cancer; 2006 Nov; 42(17):2991-5. PubMed ID: 17023156
[TBL] [Abstract][Full Text] [Related]
18. Dacarbazine-based chemotherapy for metastatic melanoma: thirty-year experience overview.
Serrone L; Zeuli M; Sega FM; Cognetti F
J Exp Clin Cancer Res; 2000 Mar; 19(1):21-34. PubMed ID: 10840932
[TBL] [Abstract][Full Text] [Related]
19. Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma.
Buzaid AC; Legha SS
Semin Oncol; 1994 Dec; 21(6 Suppl 14):23-8. PubMed ID: 7992096
[TBL] [Abstract][Full Text] [Related]
20. [Treatment of melanoma].
Dréno B; Wallon-Dumont G
Presse Med; 2003 Jan; 32(1):39-43. PubMed ID: 12610396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
